OncoSec Pushes IL-12 Approach Forward In PD-1 Melanoma Failures

24 Feb 2017

• By Emily Hayes

Company plans to pursue accelerated approval based on a single-arm registrational study of PD-1 failures, after reporting positive results from a Phase II study at the ASCO-SITC meeting.

OncoSec Medical Inc. says that its approach for delivering the anticancer protein interleukin-12 directly to tumors is likely to work in combination with PD-1 inhibition in melanoma patients who failed a PD-1 inhibitor, based on results from a small, single-arm Phase II study. It is now planning a registrational trial in PD-1 failures.

OncoSec's proprietary ImmunoPulse platform delivers DNA-based therapeutics directly into tumors, eliciting a local but also a systemic approach, according to...